Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -38.33% is 67% above its 5-year average of -115.58%, near the high end of its 5-year range (-359.78%–-32.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.93% above its 12-month average of -55.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -38.33%.
RETURN ON EQUITY (ROE)
-38.33%
RETURN ON EQUITY (ROE) AVG TTM
-55.49%
RETURN ON EQUITY (ROE) AVG 3Y
-107.26%
RETURN ON EQUITY (ROE) AVG 5Y
-115.58%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+30.93%
CURRENT VS 3Y AVG
+64.26%
CURRENT VS 5Y AVG
+66.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.54%
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
+3.06%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$267.84M
Return on Equity (ROE)
-38.33%
TTM Avg
-55.49%
3Y Avg
-107.26%
5Y Avg
-115.58%
Market Cap
$267.48M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$273.56M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
Market Cap
$264.71M
Return on Equity (ROE)
-26.24%
TTM Avg
-102.84%
3Y Avg
-107.17%
5Y Avg
-107.44%
Market Cap
$263.09M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$262.65M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
Market Cap
$262.07M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$278.58M
Return on Equity (ROE)
-82.12%
TTM Avg
-62.12%
3Y Avg
-56.53%
5Y Avg
-50.41%
Market Cap
$278.12M
Return on Equity (ROE)
-21.41%
TTM Avg
-11.72%
3Y Avg
-50.56%
5Y Avg
-98.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $267.84M | -38.33% | -55.49% | -107.26% | -115.58% |
| OraSure Technologies, Inc. (OSUR)vs › | $267.48M | -15.46% | -12.46% | -4.29% | -4.49% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $273.56M | -184.27% | -57.34% | -61.84% | -87.31% |
| Palisade Bio, Inc. (PALI)vs › | $264.71M | -26.24% | -102.84% | -107.17% | -107.44% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.09M | -39.55% | -28.46% | -79.02% | -63.95% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.65M | -37.12% | -62.34% | -32.67% | 8.91% |
| AC Immune S.A. (ACIU)vs › | $262.07M | -124.67% | -101.06% | -69.44% | -56.33% |
| Fate Therapeutics, Inc. (FATE)vs › | $278.58M | -82.12% | -62.12% | -56.53% | -50.41% |
| Aurora Cannabis Inc. (ACB)vs › | $278.12M | -21.41% | -11.72% | -50.56% | -98.46% |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.22M | -2.76% | -22.10% | -22.09% | -15.95% |
ROE
-38.3%
ROA
-36.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -38.33% |
| 2026-03-31 | -32.27% |
| 2025-12-31 | -47.02% |
| 2025-09-30 | -32.39% |
| 2025-06-30 | -127.44% |
| 2025-03-31 | -90.93% |
| 2024-12-31 | -70.94% |
| 2024-09-30 | -253.15% |
| 2024-06-30 | -153.74% |
| 2024-03-31 | -165.84% |
| 2023-09-30 | -167.79% |
| 2023-06-30 | -359.78% |
| 2023-03-31 | -280.02% |
| 2022-12-31 | -230.41% |
| 2022-09-30 | -103.38% |
| 2022-06-30 | -79.77% |
| 2022-03-31 | -102.49% |
| 2021-12-31 | -106.17% |
| 2021-09-30 | -71.14% |
| 2021-06-30 | -42.86% |
| 2021-03-31 | -33.56% |
